


In the Claims:


1-53. Cancelled.

54. Cancelled


55. (Currently amended) The compound according to claim 88 wherein B is



56. (Currently amended) The compound according to claim 55 wherein R³ is



57. (Previously presented) The compound according to claim 56 wherein R is F, Cl, Br,

I, C₁-C₃ alkyl, -C≡C-R_a,  and X is H, C₁-C₄ alkyl, F, Cl, Br or I.


58. (Previously presented) The compound according to claim 56 wherein R is CH₃, R³ is

-(CH₂)_n-C≡C-R_a, n is 0 and R_a is H.

59. (Previously presented) The compound according to claim 58 wherein R^{3a} and R^{3b} are both H.

60. (Previously presented) The compound according to claim 58 wherein R² is H.


61. (Currently amended) The compound according to claim ~~54~~ 88 which is




62. (Previously presented) The compound according to claim 61 wherein R^2 is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

63. (Previously presented) The compound according to claim 61 wherein R^2 is H.



64. (Currently amended) The compound according to claim ~~54~~ 88 wherein B is



65. (Currently amended) The compound according to claim 64 wherein R^3 is ~~CH₃~~,



66. (Previously presented) The compound according to claim 65 wherein R is H, F, Cl,

Br, I, CH₃, -C≡C-R_a,  or  and X is H, C₁-C₄ alkyl, F, Cl, Br or I.


67. (Previously presented) The compound according to claim 64 wherein R is CH₃, R³ is -(CH₂)_n-C≡C-R_a, n is 0 and R_a is H.

68. (Currently amended) The compound according to claim 67 wherein R^{3a} and R^{3b} are both H.


69. (Currently amended) The compound according to claim 68 wherein R² is H.

70. Cancelled.



71. (Currently amended) The composition according to claim ~~70~~ 89 wherein B is



72. (Previously presented) The composition according to claim 71 wherein R³ is



73. (Previously presented) The composition according to claim 72 wherein R is F, Cl, Br,


I, C₁-C₃ alkyl, -C≡C-R_a,  or  and X is H, C₁-C₄ alkyl, F, Cl, Br or I.

74. (Previously presented) The composition according to claim 71 wherein R is CH₃, R³ is -(CH₂)_n-C≡C-R_a, n is 0 and R_a is H.

75. (Previously presented) The composition according to claim 74 wherein R^{3a} and R^{3b} are both H.

76. (Previously presented) The composition according to claim 75 wherein R² is H.


77. (Currently amended) The composition according to claim ~~70~~ 89 wherein said compound is




78. (Previously presented) The composition according to claim 77 wherein R² is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester group.

79. (Previously presented) The composition according to claim 77 wherein R² is H.


80. (Currently amended) The composition according to claim ~~70~~ 89 wherein B is



81. (Currently amended) The composition according to claim 80 wherein R³ is



82. (Previously presented) The composition according to claim 81 wherein R is H, F, Cl,




83. (Previously presented) The composition according to claim 80 wherein R is CH₃, R³ is $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$, n is 0 and R_a is H.

84. (Previously presented) The composition according to claim 83 wherein R^{3a} and R^{3b} are both H.

85. (Previously presented) The composition according to claim 84 wherein R² is H.

86. (Currently amended) The composition according to claim ~~70~~ 89 wherein said compound is





Where R¹ is H or an acyl group; and

R² is H, an acyl group, a phosphate, diphosphate, triphosphate or phosphodiester

group.


87. (Previously presented) The composition according to claim 86 wherein R^1 is H and R^2 is H.

88. (New) A compound according to the formula:




Wherein B is

or



;


R is H, F, Cl, Br, I, C_1 - C_4 alkyl, $-C\equiv N$, $-C\equiv C-R_a$,



X is H, C_1 - C_4 alkyl, F, Cl, Br or I;

R^1 is H, an acyl group, a C_1 - C_{20} alkyl or an ether group;

R^2 is H, an acyl group, a C_1 - C_{20} alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R⁸ is H or a C₁-C₂₀ alkyl or ether group;

R³ is a C₃ or C₄ alkyl group, $-(\text{CH}_2)_n-\text{C}\equiv\text{C}-\text{R}_a$, $\begin{array}{c} \text{H} \\ \diagup \\ \text{---}(\text{CH}_2)_n\text{---} \end{array} \text{C}=\text{C} \begin{array}{c} \diagdown \\ \text{Y} \\ \text{H} \end{array}$ or $\begin{array}{c} \text{H} \\ \diagup \\ \text{---}(\text{CH}_2)_n\text{---} \end{array} \text{C}=\text{C} \begin{array}{c} \diagdown \\ \text{H} \\ \text{Y} \end{array}$;

R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or -C₁-C₄ alkyl;


Y is H, F, Cl, Br, I or -C₁-C₄ alkyl;


k is 0, 1 or 2; and

n is 0, 1, 2, 3, 4 or 5;



or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof.

89. (New) A pharmaceutical composition comprising an effective amount of a compound for use in the treatment of a viral disease state, disorder or a condition associated with a viral disease state according to the formula:






Wherein B is

R is H, F, Cl, Br, I, C₁-C₄ alkyl, -C≡N, -C≡C-R_a,  or  ;

X is H, C₁-C₄ alkyl, F, Cl, Br or I;



R¹ is H, an acyl group, a C₁-C₂₀ alkyl or an ether group;

R² is H, an acyl group, a C₁-C₂₀ alkyl or ether group, a phosphate, diphosphate, triphosphate, phosphodiester group or a



Nu is a radical of a biologically active antiviral compound such that an amino group or hydroxyl group from said biologically active antiviral compound forms a phosphate, phosphoramidate, carbonate or urethane group with the adjacent moiety;

R⁸ is H or a C₁-C₂₀ alkyl or ether group;

R³ is a C₃ or C₄ alkyl group, -(CH₂)_n-C≡C-R_a,  or  ;

R^{3a} and R^{3b} are each independently H, F, Cl, Br and I;

R_a is H, F, Cl, Br, I, or -C₁-C₄ alkyl;

Y is H, F, Cl, Br, I or -C₁-C₄ alkyl;

k is 0, 1 or 2; and

n is 0, 1, 2,3, 4 or 5;

or an anomer, pharmaceutically acceptable salt, polymorph or solvate thereof in combination with a pharmaceutically acceptable carrier, additive or excipient.